The DrugScience Journal:
Drug Science, Policy and Law
Drug Science, Policy and Law aims to be the definitive source of evidence-based information and comment for academics, scientists, policymakers, frontline workers and the general public on drugs and related issues. It is international in scope and grounded in a rigorous evidence base making it essential reading for all those in the field and of interest to the general public due to the jargon-free, easy to read style.
DrugScience publishes scientific review on cannabis for WHO
DrugScience has published the first scientific report on cannabis since 1935. This will enable the World Health Organization’s Expert Committee on Drug Dependence (ECDD) to conduct their first-ever review of the drug. This report could lead to a re-evaluation of the world-wide prohibition of cannabis at the UN’s Commission on Narcotic Drugs in March 2018.
Liberal Democrats call for a legalised cannabis market
Novel Psychoactive Substances - A Minimum Dataset
The collection of scientific evidence about novel psychoactive substances is essential for guiding appropriate responses and reducing harm. DrugScience has prepared the following list of fundamental pieces of information, a 'minimum dataset' that should be sought for each novel drug. This is enables future political responses to be evidence-based.
Psychoactive Substances Bill 2015
The Psychoactive Substances Bill was drafted in order to ban legal highs or "new psychoactive substances". The Bill was widely criticised by both the Home Affairs Committee and MPs and ridiculed by the press. The DrugScience group met in June 2014 and discussed the Bill. The briefing notes outline issues of priniciple, fact, definitions and recommended ammendments to remedy them.
Drug Driving Consultation 2013
DrugScience responds to the UK Government's Drug Driving Consultation 2013. The UK Government elected to enforce a "zero-tolerance" policy to 8 controlled drugs. However, for alcohol and other controlled drugs which are no less dangerous when driving, a rational risk-based approach is used. This decision runs contrary to the advice given by its own Advisory Council.
Amphetamine Driving Consultation 2015
As amphetamine is prescribed in the treatment of ADHD, it was omitted from the 2013 Drug Driving consultation until a suitable limit could be decided upon. The UK Government settled upon a limit of 50µg/L. DrugScience, with the aid of ADHD experts, discusses how this is a) neither evidence-lead nor rational b) will discourage patients from taking necessary medication and c) further discriminate against ADHD patients.
European Drug Law
Use our interactive map to browse drug laws within the EU.